Recently re-appointed as Chair of the Detection, Diagnosis and Prognosis-2 (DDP-1) peer review panel for the Fiscal Year 2025 Prostate Cancer Research Program (PCRP) within the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP). Dr. Kohli has served in this leadership role since 2022, reflecting the program’s continued confidence in his expertise and dedication to improving prostate cancer outcomes. This prestigious program, which currently has an allocation of $110 million for FY25, supports innovative research aimed at advancing the understanding and treatment of prostate cancer.